new glp-1 drug Eli Lilly to seek approval of weight-loss this year GLP-1 drugs protect against new

JAMA 2025, 333, 113114

Plaintiffs in these lawsuits allege that some patients developed life-altering complications including gastroparesis, bowel obstruction, cyclic vomiting syndrome, gallbladder disease, pulmonary aspiration during surgery, and sudden vision loss associated with non-arteritic anterior ischemic optic neuropathy (NAION)

doi: 10.1177/1060028017698496

GLP-1RA promotes brown adipogenesis of C3H10T1/2 mesenchymal stem cells via the PI3K-AKT-mTOR signaling pathway

GLP-1 receptors are very widely distributed, particularly in the brain, says Daniel Drucker, an endocrinologist at the University of Toronto, who has consulted for Novo Nordisk, Eli Lilly and other companies developing weight-loss drugs

Current suicidal thoughts and/or prior suicidal attempt 6